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Activity-dependent, polyneuronal synapse elimination (ADPSE) is a programmed, regressive event in the development of
the nervous system and readily studied at the neuromuscular junction, where it is complete 15±20 days after birth. Local
excess, or imbalanced, protease activity is one of several possible underlying mechanisms. In this regard, thrombin mediates
activity-dependent synapse loss in an in vitro model of ADPSE. To test the involvement of thrombin in vivo, we locally
applied the leech thrombin-speci®c inhibitor, hirudin. We monitored neuromuscular behavior, correlated with acetylcholin-
esterase and silver nitrate histochemistry at endplates, for changes in the timecourse of in vivo synapse elimination and
assayed both thrombin activity and prothrombin expression in developing muscle. Hirudin retarded elimination, without
altering motor performance, uniquely at Postnatal Day 5 (P5) and maximally at P9. Reverse transcription±polymerase
chain reaction (PCR) showed that neonatal muscle was a source of local prothrombin, with peak expression during the
®rst week after birth. A speci®c chromogenic assay revealed that local thrombin, activated from muscle-derived prothrom-
bin, peaked during maximal synapse remodeling. q 1996 Academic Press, Inc.
INTRODUCTION anced, excess local protease activity have been hypothe-
sized (Changeux and Danchin, 1976; Connold et al., 1986;
Festoff, 1987; O'Brien et al., 1978, 1984; VrbovaÂ and Fisher,The change from perinatal, multineuronal, or polyneuro-
1989). Local protease excess has been particularly attractive,nal innervation of skeletal muscle to the adult mononeuro-
since this proposed mechanism, implicating degradation ofnal state carries the implication of removal or elimination
one or more critical extracellular matrix (ECM) adhesionof initial synaptic connections. Synapse elimination occurs
molecules (Connold et al., 1986; O'Brien et al., 1978), isduring this developmental time period, not only in muscle,
consistent with the phenomena of simple retraction with-but in all parts of the nervous system and in all species.
out degeneration, previously found by several authorsMost studies point to synaptic competition among ``domi-
(Riley, 1977; VrbovaÂ and Fisher, 1989). The proteases sug-nant'' and ``subordinate'' synaptic terminals; however, the
gested have included a thiol-based, calcium-activated neu-speci®c molecular mechanism of synapse elimination is not
tral protease (Connold et al., 1986; VrbovaÂ and Fisher, 1989)known (Colman and Lichtman, 1993; Lichtman and Balice-
and plasminogen activators (PAs), particularly urokinase-Gordon, 1990; Purves and Lichtman, 1980; Van Essen, 1982;
like PA (HantaõÈ et al., 1989).Van Essen et al., 1990). Of the several potential mechanistic
Using an in vitro model, which reproduced the activityprocesses, competition between terminals, based on dwin-
dependence and leupeptin sensitivity seen in vivo (Connolddling supplies of essential neurotrophic factors, and imbal-
et al., 1986), we unexpectedly found that thrombin (Fenton,
1986) serine proteolytic activity was required for activity-
dependent synapse elimination (Liu et al., 1994a,b). Demon-1 To whom correspondence should be addressed at Neurobiology
strating speci®city for thrombin in this same system, syn-Research Lab (151R), VA Medical Center, 4801 Linwood Boulevard,
apse reduction was not blocked by inhibitors of plasmin,Kansas City, MO 64128. Fax: (816) 922-3375. E-mail: serpin@
kuhub.cc.ukans.edu. trypsin, or cysteine proteases (1 mM aprotinin, cystatin) or
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tized with an ip injection of 20 ml/g of rodent cocktail (ketaminetwo calcium-activating neutral protease (calpain I and II)
5 mg/ml; 5% v/v acepromazine in PBS), a small dorsal skin incisioninhibitors. Only hirudin (Fenton, 1989) and protease nexin
was made, and a mini-osmotic pump (Alzet, 1007 D; Alza Corp.,I (PNI) (Scott et al., 1985), potent inhibitors of thrombin, at
Palo Alto, CA), ®lled with 100 ml hirudin (100 mM in PBS) or vehicle,nanomolar concentrations, blocked synapse loss.
was inserted. In separate preliminary experiments, we con®rmed,
using thrombin inhibition assays with the speci®c S-2238 sub-
strate, that hirudin maintains its activity over 5 days in a pump at
MATERIALS AND METHODS 377C. The pump was attached to a ®ne-bore Te¯on catheter which
released 0.52 { 0.02 ml/hr with the catheter free end directed to
the surface of the left gastrocnemius muscle. The skin incision wasAnimals and animal husbandry. BALB/c female mice 8±9
sealed with cyanoacrylate adhesive (Zoubine et al., in preparation)weeks old, weighing 18±20 g, were mated to obtain normal off-
and the pup was returned to its mother. Intramuscular injectionsspring. Pregnant females were housed in our Animal Research Fa-
were replaced by this pump delivery on P7.cility, kept to a 12-hr light/dark cycle, and allowed rodent chow
Neuromuscular behavior. Spontaneous placing and rightingad libitum. All procedures were approved by the Animal Studies
activities were carefully observed and recorded before, during, andCommittee and adhered to NIH guidelines.
after intramuscular injection and implanting of osmotic pumps andMuscle dissection, endplate counting, and staining. Gastrocne-
catheters. Activity was identical for hirudin-treated mice (compar-mius muscles were removed from neonates at Postnatal Days P1,
ing right and left sides) and for PBS-injected and nonoperated lit-P5, P9, P13, P15, P18, and P22, mounted, frozen in OCT compound
termates. There was no difference in the behavior of the mothersin liquid nitrogen, and stored at 0707C until used. Longitudinal
toward treated pups compared with untreated, and all pups weresections (50±60 mm) were cut in a Hacker±Bright cryostat at0187C.
handled by examiners in the same way.A drop of EDTA solution was placed on the sections to prevent
Muscle tissue extraction. We performed all assays with frozenmuscle contraction, and slides were air-dried and stored at 0707C.
muscle stored at 0707C. Consequently, suf®cient samples for theFor staining with anti-synaptophysin antibody (Boehringer
entire temporal course (i.e., E14 through P30) were collected priorMannheim, Indianapolis, IN) and tetramethylrhodamine-a-bunga-
to assay. For the earlier developmental time points, three to ®verotoxin (TMR-a-BTX, Molecular Probes, Eugene, OR), slides were
treated as previously described (Ma et al., 1994) and then preincu- embryonic samples were pooled. Prior to assay all tissues were
bated with 10% donkey serum in phosphate-buffered saline (PBS) thawed on ice, homogenized with a glass±glass conical homoge-
for 1 hr at room temperature. Following this, anti-synaptophysin nizer in ice-cold aqueous homogenization buffer (250 mM sucrose,
antibody was added at a 1:100 dilution and the slides were placed 1.0 mM EDTA, 0.9% NaCl, 50 mM Tris±HCl, pH 7.4), and centri-
at 47C for 18 hr in a humidity chamber. The slides were then fuged at 17,500g in a Beckman G15R refrigerated centrifuge
washed in PBS followed by incubation with donkey anti-rabbit IgG equipped with an F2404 rotor for 15 min. The resulting superna-
(H / L) conjugated with dichlorotriazinylamino ¯uorescein (Jack- tants (S1) were saved for assay. Protein concentration was deter-
son ImmunoResearch, West Grove, PA) at a 1:300 dilution. After mined using bicinchoninic acid protein assay reagent (Pierce Bio-
an additional wash with PBS, slides were incubated with 10 nM chemical, Rockford, IL) according to the manufacturer's recom-
TMR-a-BTX for 5 min. Hoechst AG Mowiol 4-88 medium (Calbio- mendations.
chem, La Jolla, CA) was added, coverslips were placed, and slides Thrombin chromogenic (S-2238 amidolytic) assay. We mea-
were viewed using epi¯uorescence with a Leitz Orthoplan micro- sured thrombin activity in extracts from rinsed (embryonic and
scope and Ploem ®lters. early postnatal) or perfused (later postnatal and adult) muscle with
To observe axonal inputs to endplates, sections were ®xed in 4% an amidolytic assay by quantifying the thrombin-mediated cleav-
paraformaldehyde in phosphate buffer (pH 7.2) for 2 hr at room age of a synthetic tripeptide substrate, D-Phe-Pip-Arg-p-nitroanilide
temperature, washed in double-distilled water, and stained with (pNA) (S-2238) (Kabi Pharmacia Hepar. Inc, Franklin, OH). Either
acetylthiocholine iodide combined with impregnation of nerves samples (10 ml) or dilutions of standard human a-thrombin (gener-
with 1% silver nitrate (HantaõÈ et al., 1989). The counting of poly- ous gift from Dr. J. W. Fenton, II, Wadsworth Center for Labora-
and mononeuronally innervated endplates (EPs) from indepen- tories and Research, Albany, NY), ranging from 1 to 20 nM, were
dently coded slides was performed ``blind'' by three individuals. mixed with 25 ml of S-2238 (1 mg/ml) and adjusted to 200 ml with
Three ®elds in each of six sections per muscle were counted by assay buffer (0.05 M Tris±HCl, pH 8.3, containing 0.15 M NaCl).
each individual. The data were decoded, organized in a table, and Samples were incubated at 377C in 96-well, ¯at-bottomed microti-
analyzed by the sign test for statistical signi®cance (Siegel, 1956). ter plates (Imulon 2, Dynatech Laboratories, Inc., Chantilly, VA)
The following formula was used: and monitored for the release of pNA at 410 nm with the MR 5000
microplate reader (Dynatech). Controls (including buffer, substrate,
and extracts alone) were assayed in parallel wells, with duplicatepercentage polyneuronal innervation (%)
wells for each sample, and subtracted from experimental values.
The concentration of thrombin in samples was calculated with No. of EPs with 2 or more axon terminals
Total No. of EPs
1 100.
reference to a standard curve obtained with puri®ed human a-
thrombin that was assayed simultaneously. The amidolytic activ-
ity was expressed as units per milligram protein, where one unitHirudin administration. On P5 (day of birth, P0) one intramus-
is de®ned as one nanomole of cleaved substrate per hour. An absorp-cular injection of 15 ml hirudin (Sigma, St. Louis, MO), at 1 mM in
tion coef®cient of 9920 M01 cm01 for pNA was used (Witting etPBS, or vehicle using an ultrathin, 32-gauge steel needle (Hamilton
al., 1987). Values listed represent means { SDs of three separateCo., Reno, NV), was made in posterior hindlimb muscles and re-
assays.peated again in 24 hr. Injection was made in the long axis of the
Prothrombin mRNA determination. RNA was extracted in themuscle and only on withdrawal (English and Schwartz, 1995), to
minimize injury and leakage of solution. On P7, mice were anesthe- presence of denaturants and veri®ed both by methylene blue stain-
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ing and spectrophotometrically. The PCR primers, 5*GAGAAG- 82 { 12 (SEM)% of the total EPs at P5, 44 { 11 (SEM)% at
GGTATCGCCCCCTG and 5*TGTCTGCTTGTCTGGCAAAC, P9, and 11 { 5% at P15, a naturally occurring loss of 87%
synthesized by DNA International (Lake Oswego, OR), were chosen of polyneuronal innervation during these 10 days. We calcu-
to amplify the mRNA segment 1120±1473 of mouse prothrombin lated the rate of synapse elimination between P5 and P15,
(GenBank Accession No. X52308) (Degen et al., 1990). RT-PCR, which showed that 7.1% of excess synapses were lost per
optimized for subplateau signals using GeneAmp EZ rTth polymer-
day (Fig. 3). Three rates can be discerned in natural ADPSEase (Perkin±Elmer, Norwalk, CT) per the manufacturer's recom-
in mouse gastrocnemius: a shallow slope between P1 andmendations, was performed with 0.45 mM 3* and 5* oligonucleo-
P5, a much steeper slope between P5 and P15, and a third,tides and 0.5±1 mg total RNA. Initial cDNA synthesis at 607C for
much slower, or no rate of loss, after P15.30 min was followed by incubation at 947C for 2 min and then
40 cycles of ampli®cation (947C denaturation and 607C annealing
extension; 1 min each). Products were visualized with ethidium
Effects of Local Hirudin on Synapse Lossbromide after electrophoresis on 3% metaphor agarose (FMC, Rock-
land, ME). Having examined naturally occurring ADPSE, we next
evaluated the effects of local application of hirudin (Fenton
et al., 1991) on this elimination. We injected the leech
thrombin inhibitor intramuscularly for 2 days starting atRESULTS
P5, since our data indicated the greatest remodeling after
this date. Then, beginning on P7, we replaced injectionsTimecourse of Polyneuronal Synapse Loss
with rate-controlled, local delivery of hirudin by a subcuta-
neously implanted osmotic mini-pump and a ®ne catheterThe neuromuscular junction (NMJ) is the best understood
vertebrate synapse (Hall and Sanes, 1993) and a useful model placed over the gastrocnemius muscle. The hirudin-treated
animals appeared no different than untreated littermates.for investigation of synaptic plasticity (Balice-Gordon et al.,
1990, 1993; Balice-Gordon and Lichtman, 1990). Over the Importantly, no impairment of motor function was detected
on the hirudin-treated side compared to the contralateral®rst 3 weeks of life, we observed a maturation of the NMJs
evidenced at low power by an apparent overall increase in leg. Consequently, the results of counting mono- and poly-
neuronal-innervated neuromuscular synapses in BALB/cthe presynaptic marker, synaptophysin (Figs. 1A, 1C, and
1E), relative to the acetylcholine receptors (AChRs) stained mice at P9, following 4 days of hirudin treatment, were
judged to be unrelated to the degree or extent of nerve-with TMR-a-BTX (Figs. 1B, 1D, and 1F). Although the num-
ber of synapses at each endplate is decreasing during this evoked muscle activity.
We removed leg muscles at P9 and P15, ¯ash-froze them,period, the local levels of at least one presynaptic protein are
increasing, perhaps re¯ecting the structural and functional and used the silver-AChE technique to obtain the percentage
of polyneuronal-innervated EPs after hirudin treatment. Nostate of the developed endplate. Although indistinguishable
at this level, this change would be consistent with the re- evidence of in¯ammatory cell reaction (lymphocytes or mac-
rophages) was found and needle tracks were not seen. Moreplacement of less active presynaptic termini, as well as
other alterations that could affect the staining. In any case, than 4000 EPs were counted in these experiments and the
results indicated a marked effect on the elimination time-the colocalization of the pre- and postsynaptic markers in
the sections under investigation is shown. course by the thrombin inhibitor. We found that muscles satu-
rated locally with hirudin had a greater number of polyneuro-For this study of molecular mechanisms of synapse elimi-
nation, we ®rst established the natural timecourse of activ- nal-innervated EPs than did the contralateral control muscles.
In a representative series, a total of 1845 EPs were counted atity-dependent, polyneuronal synapse elimination (ADPSE)
in ¯ash-frozen mouse gastrocnemius muscle removed from P9 (n  5 mice); 816 hirudin-treated EPs and 1029 EPs were
counted in control, contralateral muscles. The average per-P1 to P22 mice, using the silver-AChE staining technique
(HantaõÈ et al., 1989; Ma et al., 1994; Tian et al., 1995). This centage of polyneuronal-innervated EPs on the hirudin-treated
side was 80 { 7%. On the contralateral control side, this wastechnique has the advantage of enabling large numbers of
EPs to be examined individually. However, in contrast to 51 { 9% (Fig. 4A). The latter number correlated with the 44
{ 11% that we found during the natural postnatal eliminationelectrical measurements, it may include a few axonal
branchings derived from the same primary axon. Although timecourse (Fig. 3). We found that hirudin-treated EPs had
56% greater polyneuronal innervation compared to controlin embryos each muscle ®ber is innervated by three to four
different axons, after birth, the majority of EPs are doubly EPs, which was statistically signi®cant (P  0.05, sign test
(Siegel, 1956)). In other experiments (Fig. 4A), we con®rmedinnervated (Dennis, 1981). These are then removed to arrive
at a single, mononeuronal innervation. With this technique, that this was dependent on hirudin and not the injection since
PBS, both injected into muscle and delivered by pump, re-poly- and mononeuronal-innervated EPs were clearly distin-
guished during the postnatal period, as shown in the repre- sulted in 40 { 12% polyneuronal innervation. As we found
with hirudin, saline injection into muscle and infusion bysentative photomicrographs (Fig. 2). We quanti®ed these
results using the formula presented above, and these analy- pump caused no signs of diminished neuromuscular activity.
These results further con®rmed that pump and catheter place-ses are graphically presented in Figs. 3 and 4. Polyneuronal
synapses, de®ned as EPs with two or more inputs, represent ment had no effect on nerve-evoked muscle activity.
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FIG. 1. Endplates in mouse gastrocnemius muscle at Postnatal Days 1 (P1; A, B), P9 (C, D), and P21 (E, F). The synapses are stained
with antibody to the presynaptic marker anti-synaptophysin (A, C, E) or with TMR-a-bungarotoxin for postsynaptic AChRs (B, D, F).
During development, there is progressive intensity, but an apparent reduced frequency, of synaptophysin.
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FIG. 2. Naturally occurring polyneuronal synapse elimination in mouse gastrocnemius muscle. (A) Both polyaxonal innervation (arrows)
and monoaxonal innervation (.) at EPs are clearly visible at P9. (B) Primarily monoaxonal innervation (.) is found in gastrocnemius
muscles at P15. Scale bar, 10 mm.
Since the majority of polyneuronally innervated EPs have tion of EPs on P15, after 10 days of hirudin treatment, none-
theless showed that hirudin still delayed synapse elimination.already been eliminated by P15, we expected the effect of
hirudin to be less obvious at this stage than at P9. Our control A total of 2102 EPs were counted at P15: 1264 on the hirudin-
treated side and 838 in contralateral, control muscles. Thedata, in fact, show that only 11 { 5% of EPs remain multiply
innervated at P15 (see Fig. 3). Results obtained from examina- average percentage of polyneuronal-innervated EPs (n 6 ani-
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grammed timecourse of polyneuronal synapse elimination
with the pro®le observed in the presence of hirudin. The delay
in the elimination attributable to the effects of hirudin was
clearly more evident at the earlier time point selected (P9).
However, statistically signi®cant differences between treated
and control EPs were still detected at P15. With hirudin, over
the ®rst half of this timecourse (P5±P9), synapse loss was only
0.9% per day, compared with 12% lost per day naturally.
Comparing the half-maximal decrease in polyneuronally in-
nervated EPs in controls to the hirudin-treated muscles indi-
cates that the elimination process was delayed approximately
4 days (from 8.5 to 12.5) by hirudin.
Prothrombin Gene Expression
The leech protein, hirudin, is a speci®c and potent throm-
FIG. 3. The timecourse of synapse loss in active postnatal mouse bin inhibitor, implicating thrombin activity in any parame-
muscle. P9 and P15 synapse counts from muscles infused with the ter affected by hirudin (Fenton et al., 1991). Since hirudin
thrombin inhibitor, hirudin (solid line), were compared to control
had a dramatic effect at the time of maximal synapse remod-polyneuronal innervation data (dashed line) collected from un-
eling in muscle, and this effect was mediated by inhibitingtreated animals, contralateral muscles, and muscles treated with
its cognate protease, thrombin, an important questionPBS.
raised by our results is the source of thrombin activity that
is potently inhibited by local hirudin to delay ADPSE in
neonatal muscle. Thrombin, as prothrombin, would be ex-
pected to be in the muscle vascular bed and might be acti-mals) was 22 { 3% in hirudin-treated muscles while in the
untreated, contralateral controls it was 14 { 3% (Fig. 4B). vated locally by prothrombinase (Benzakour et al., 1995;
Fenton, 1988). However, prothrombin expression has pre-The hirudin-treated side at P15 had a 57% greater number of
polyneuronal-innervated NMJs compared to control (P 0.05, viously been detected in rat brain, where it is maximally
expressed before birth (Dihanich et al., 1991), indicatingsign test). Figure 3 compares our data for the natural pro-
FIG. 4. Effects of hirudin on polyneuronal-innervated EPs in mouse gastrocnemius muscle. Mice were treated with hirudin, beginning
at P5. As before (Fig. 1), muscles were removed, frozen, sectioned, and stained with silver-AChE. The formula under Materials and Methods
was used to determine the effects of hirudin on percentage of polyneuronal innervation. EPs of treated muscle, under constant hirudin
exposure, were compared with contralateral muscle and with both untreated littermate and PBS-treated controls at (A) P9 and (B) P15.
The scale in B is 0±30% polyneuronal endplates. The P values were determined using the sign test (Siegel, 1956).
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FIG. 5. Prothrombin RT-PCR of mouse gastrocnemius muscle. Total RNA was extracted from developing muscle at different develop-
mental times from Embryonic Day 12 (E12) to P30, reverse transcribed, and ampli®ed by PCR to subplateau levels. N, negative control
(no template); and L, positive control (liver RNA).
that tissues other than liver (Fenton, 1986) might also ex- hibitor dramatically delays programmed synapse elimina-
tion, but it also offers molecular evidence to speci®callypress prothrombin. That muscle may be a source of this
thrombin precursor, and may be implicated in synapse re- support the ``protease hypothesis'' of synapse elimination
modeling, is further supported by alterations in measurable (Festoff, 1980; O'Brien et al., 1978). This delay (Fig. 3), with-
thrombin activity released from cultured myotubes, af- out concomitant effects on muscle activity, correlates with
fected by agents that in¯uence activity (Nelson et al., 1994). both prothrombin gene expression and thrombin activity in
Furthermore, since hirudin delayed but did not totally block muscle at a time in postnatal development during extensive
elimination, this suggested that thrombin might be locally synapse remodeling. These effects in the mouse gastrocne-
generated in neonatal muscle and may be developmentally mius, as revealed by changes in the morphology of such
regulated. This implies that the muscle ®ber itself might remodeling, were greatest between P5 and P9 (Fig. 4A), the
be the source of released prothrombin which is activated to time for maximum synapse elimination in mouse muscle,
thrombin in the vicinity of the synaptic cleft. and were relatively complete by P15 (Fig. 4B) (Colman and
With this in mind, and as a ®rst step to assessing changes Lichtman, 1993). Less remodeling is taking place in muscle
in local thrombin protein levels, we determined whether at this later time, and less prothrombin expression and
prothrombin gene expression was detectable in postnatal thrombin activity (Figs. 5, 6), which correlate with less ef-
skeletal muscle. We used RT-PCR and found that muscle fect of the thrombin inhibitor.
did, indeed, express prothrombin, with peak prothrombin Previous models relating to synapse elimination in mus-
mRNA during the ®nal phase of ADPSE (Fig. 5). Expression cle have not focused on speci®c molecular mechanisms.
decreased considerably after P7, but prothrombin mRNA However, the work of Lichtman and colleagues (Balice-Gor-
was still detected until P20. don et al., 1990, 1993; Balice-Gordon and Lichtman, 1990,
1994; Colman and Lichtman, 1993; Lichtman and Balice-
Gordon, 1990) have emphasized the restricted, local natureThrombin Amidolytic Activity
of the elimination process. The contributions of VrbovaÂ and
Since it is thrombin's proteolytic activity, and not just her colleagues have called attention to the possibility that
prothrombin expression, that is implicated in synapse re- proteases, acting on ECM adhesive macromolecules, may
moval by these experiments, we also assayed amidolytic be important (Connold et al., 1986; O'Brien et al., 1984;
activity that is speci®c for thrombin. We found that such VrbovaÂ and Fisher, 1989). Our own studies have implicated
activity is detected at P15, but it is much greater at earlier a developmental imbalance of serine proteases and their
postnatal times. Although thrombin activity was detectable serpin inhibitors in driving the wave of ADPSE in muscle
as early as E14, it was biphasic, elevated at E18 and greater (Festoff, 1980; HantaõÈ et al., 1989). Our recent studies point
at P10, where the maximal peak was found (Fig. 6A). This to an imbalance between the coagulation protease, throm-
activity was inhibited by thrombin inhibitors, such as D- bin (Liu et al., 1994a,b), and its principal serpin in tissues,
Phe-Pro-Arg-chloromethyl ketone (PPACK) and PNI, in ad- PNI (Akaaboune et al., 1995; Festoff et al., 1991; VerdieÁre-
dition to hirudin (not shown). In addition, prothrombin lev- SahuqueÂ et al., 1996).
els, as measured by ecarin activation of muscle extracts The reduced effect of hirudin at P15 (Fig. 4B) indicates
(Rosing and Tans, 1988), also revealed developmental regu- that hirudin delays but does not prevent ADPSE. This may
lation (Fig. 6B), re¯ecting local synthesis of the precursor. correlate with prothrombin expression downregulation
after the wave of ADPSE is complete. It also suggests that
the inhibitor has less effect, since more polyneuronal EPs
DISCUSSION have been eliminated and less protease is locally produced
to inhibit, perhaps, in conjunction with reduced hirudin
activity released from the pump over time. Although we didThese results are novel and informative, since not only
is this the ®rst demonstration that a speci®c thrombin in- not directly estimate residual activity of hirudin in pumps
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FIG. 6. Thrombin (A) and ecarin-activated prothrombin (B) amidolytic activity during neuromuscular development determined by cleavage
of the speci®c substrate S-2238.
removed from animals, we did do separate experiments to to, and cleavage of, the PART receptor may also initiate
other signal transduction/molecular mechanisms underly-determine the stability of hirudin in pumps maintained at
377C in a humid environment. These studies showed no ing the process of selection of active synapses. Such changes
might affect clusters of AChRs, leading to their disaggrega-decrease in hirudin's potency to inhibit thrombin in the S-
2238 assay (not shown). Thus, in this regard, the neonatal tion and further promoting terminal retraction (Balice-Gor-
don and Lichtman, 1994). The current results, demonstra-muscle ®ber appears to be a signi®cant source of zymogen
prothrombin, but the ``window of opportunity'' for a throm- ting the importance of thrombin activity in elimination,
are consistent with the localization of PART at the synapse,bin inhibitor appears restricted, based on the availability of
the protease, its precursor and/or activator (prothrombinase) where it may be activated by thrombin-directed proteolysis
after thrombin binding, via its anion exosite I, to the hiru-at the synaptic site.
Most, if not all, of thrombin's effects in the nervous sys- din-like domain of the receptor. However, this is currently
not known, but may be easily tested in model systems sincetem are mediated via the seven-transmembrane-domain,
proteolytically activated receptor for thrombin (PART) the many components of the thrombin signaling system are
now available for study.(Hung et al., 1992; Vu et al., 1991), since thrombin receptor
activating peptides produce the same effect as thrombin on For inhibition of released thrombin before its interaction
with the PART, PNI, the most potent mammalian throm-neurite and astrocyte process retraction (Beecher et al.,
1994; Jalink and Moolenaar, 1992; Suidan et al., 1992). Al- bin inhibitor found in tissues (Farrell et al., 1988; Stone
et al., 1987), is likely the physiologic regulator of excessthough hirudin would not be expected to be present at the
mouse NMJ, mouse PART has a hirudin-like domain, with thrombin action in ADPSE. From our prior studies, PNI
closely colocalizes with AChRs at the adult mouse NMJ,the sequence KYEPF-WEDEE (Ishii et al., 1995), which is
expressed in skeletal muscle (Niclou et al., 1994). This do- appearing later than the peak of prothrombin expression
in neonatal muscle and localizing to the synapse after P5main would be free to participate in thrombin binding at
its anion-binding exosite I, after prothrombin secretion and (Akaaboune et al., 1995; Festoff et al., 1991). In this regard,
PNI blocked ADPSE in the same nanomolar concentrationactivation. Signal transduction through this receptor is G-
protein-coupled and functions to mobilize [Ca2/]i within the range as hirudin in our in vitro model (Liu et al., 1994a).
PNI, a serpin identical to the glia-derived nexin, is regu-respective cells (Pouyssegur et al., 1993). [Ca2/]i mobiliza-
tion might then be able to depolymerize microtubules and lated by factors related to cell activity and injury (Monard,
1993; Monard et al., 1990). It is released from glial cells,neuro®laments in distal axons, possibly with the participa-
tion of the small 21-kDa Ras G-protein, Rho (Jalink et al., activated by injury-related cytokines and by vasoactive in-
testinal polypeptide (Bleuel et al., 1995; Cunningham et1994). It may also raise intracellular, calcium-activated neu-
tral proteases, such as calpains, to further promote retrac- al., 1993; Festoff et al., 1996), and binds to the cell surface
and/or the ECM, where it forms SDS-resistant complexestion of subordinate terminals from EPs. This may explain,
in part, the observation by VrbovaÂ and colleagues that milli- with thrombin, which are then internalized and degraded
within the cell (Baker et al., 1980; VerdieÁ re-SahuqueÂ et al.,molar concentrations of calpain inhibitors also caused retar-
dation of ADPSE (Connold et al., 1986). Binding of thrombin 1996). Binding of PNI to the ECM of the NMJ may be to
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rence Brass (University of Pennsylvania), Ann Lohof (UniversiteÂ de``receptors,'' such as collagen IV, vitronectin (Donovan et
Paris VII), Peter Smith (University of Kansas Medical Center), andal., 1994; Rovelli et al., 1990), or others, to inactivate ex-
Albert Herrera (University of Southern California) for critical read-cess thrombin. This would function to produce a spatially
ing of the manuscript. Part of this work was performed during anand temporally restricted neutralization of thrombin pro-
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